Categories: News

cbdMD, Inc. to Host Conference Call to Discuss Third Quarter of Fiscal 2024 Results

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Charlotte, North Carolina–(Newsfile Corp. – August 5, 2024) – cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBD-PA), one of the nation’s leading, highly trusted and widely recognized CBD companies, today announces that it will host a conference call at 4:20 p.m., Eastern Time, on Wednesday, August 14, 2024, to discuss the company’s June 30, 2024 third quarter of fiscal 2024 financial results and business progress.

CONFERENCE CALL DETAILS

Wednesday August 14, 2024, 4:20 p.m. Eastern Time
USA/Canada: 844-763-8274
International: 647-484-8814

Teleconference Replay dial in:
USA/Canada: 877-344-7529
International: 412-317-0088
Replay Passcode: 5067217
Webcast/Webcast Replay link – available through August 14, 2025:

https://www.gowebcasting.com/13431

About cbdMD, Inc.

cbdMD, Inc. is one of the leading and most highly trusted and recognized hemp-derived cannabidiol (CBD) brands with a comprehensive line of U.S. produced, THC-free1 CBD products as well as Full Spectrum and Delta 9 THC products. The cbdMD brand currently includes high-quality, premium CBD products including tinctures, gummies, topicals, capsules, sleep aids and more. The Company’s Paw CBD brand includes formulated pet products including tinctures, chews and topicals in varying strengths. cbdMD also operates ATRx Labs, a line of functional mushroom supplements. To learn more about cbdMD and the complete line of products, please visit www.cbdmd.com, follow cbdMD on Instagram and Facebook or visit one of the thousands of retail outlets that carry cbdMD products.

1 THC-free is defined as below the level of detection using validated scientific analytical tools.

Contact Information:

cbdMD, Inc.
Ronan Kennedy, CEO
Phone: +1 (704) 445-3064 email: IR@cbdmd.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/218832

Staff

Recent Posts

NJ Rallies Investment Power, Leveraging Capital from Garden State Venture Partners to Drive MedTech and Maternal Health Innovation

GLASSBORO, N.J.--(BUSINESS WIRE)--Two transformative healthcare announcements this week mark a new era for New Jersey’s…

5 hours ago

Revival Healthcare Capital Announces Strategic Partnership to Accelerate External Innovation in Robotics With up to $458 Million Joint Investment With Olympus Into Co-Founded New Company Swan EndoSurgical

AUSTIN, Texas--(BUSINESS WIRE)--Revival Healthcare Capital (Revival), an investment firm focused on transformative external innovation partnerships…

5 hours ago

Establishment Labs to Announce Second Quarter 2025 Financial Results on August 7

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to…

8 hours ago

HCA Healthcare Reports Second Quarter 2025 Results

Raises 2025 GuidanceNASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results…

8 hours ago

Numinus Wellness Inc. Announces Fourth Quarter Fiscal 2024 Results

Q4 Fiscal 2024 Highlights1Revenue of $1.2 million, a 16.4% increase over Q3 2024Gross profit of…

8 hours ago

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO),…

11 hours ago